Long‐Term Outcome of Neuro‐Behçet's Disease

Abstract

Objective. To report the long-term outcome of neurologic involvement in patients with Behçet's disease (BD).Methods. We performed a retrospective analysis of 115 patients who fulfilled the international criteria for BD (57% male; median age 37 years [interquartile range (IQR) 30-46 years]) and had neuro-BD (NBD) after exclusion of cerebral venous thrombosis. Factors associated with relapse of NBD, inability to perform activities of daily living, and mortality were assessed.Results. Seventy-eight patients (68%) presented with acute NBD and 37 (32%) presented with a progressive course. The HLA-B51 allele was carried by 49% of the patients. Overall, 46 of 115 patients (40%) had severe disability at baseline, represented by a Rankin score of >3. The 5-and 7-year event-free survival rates were 65% and 53%, respectively. In multivariate analysis, a positive HLA-B51 status was independently associated with the risk of NBD relapse, with an odds ratio (OR) of 3.6 (95% confidence interval [95% CI] 1.5-9.1). Conclusion. Our findings indicate that NBD is a severe condition in which patients with the HLA-B51 allele appear to experience a worse prognosis. After a median followup of 73 months (IQR

Effects of Smoking and HLA-B51 on Clinical Manifestations in Behçet’s Disease: Retrospective Analysis of 209 Patients in a Turkish Population

“…[13][14][15][16] Results of these studies partially support our findings, but they have not examined whether patients smoke or not. Bilgin et al 2 have also reported that cystoid macular edema among current smoking patients with BD was significantly higher than nonsmoking patients, but smoking was inefficient on other ocular involvement.…”

Efficacy of anti-TNF alpha in severe and/or refractory Behçet's disease: Multicenter study of 124 patients

“…Corticosteroid sparing was defined as a significant decrease of corticosteroid daily dose between the day of anti-TNF introduction and after 6 and 12 months of treatment. Relapses were defined as an occurrence of new BD manifestations and/or worsening of a preexisting manifestation requiring treatment intensification or modification [15,20,26]. Safety was assessed by the occurrence of side effects.…”

Retrospective analysis of long-term outcome of chronic progressive neurological manifestations in Behcet's disease

“…We have previously revealed that the positive rate of HLA-B51 was nearly 90% in CPNBD [10,21]. Consistently, it has been shown that a positive HLA-B51 status was associated with a worse prognosis [20]. More importantly, no patients were given methotrexate, whereas all the patients were given corticosteroid and approximately 80% of the patients were given cyclophosphamide or azathioprine in the study [20].…”

“…Recent studies have confirmed the poor long-term outcome of NBD [20]. It appears that the poor outcome might be a result of the presence of patients with CPNBD.…”